Диагностика и лечение артериальной гипертонии

Представленные Рекомендации являются обновленной версией Российских рекомендаций по диагностике и лечению артериальной гипертонии от 2016 г. и зарубежных рекомендаций по лечению артериальной гипертонии Европейского общества гипертонии и Европейского общества кардиологов от 2018 г., которые, в свою очередь, были созданы на основе анализа имеющегося более чем 20-летнего опыта разных по целям, протоколам и объемам крупных исследований, проведенных по различным аспектам диагностики и лечения артериальной гипертонии (АГ). Кроме того, в разделах Рекомендаций, посвященных методам контроля артериального давления (АД), диагностике и лечению АГ, учтен опыт отечественных исследований. В Рекомендациях изложены основные принципы лечения пациентов с АГ, в том числе и в ряде клинических ситуаций, которые были получены в рандомизированных контролируемых исследованиях (РКИ), вместе с тем важен учет индивидуальных особенностей механизмов развития и течения заболевания, например, солечувствительности, вторичного гиперальдостеронизма при гипертонической болезни (ГБ), индивидуальной чувствительности к антигипертензивным препаратам (АГП), что оставляет право и целесообразность осуществлять подбор антигипертензивной терапии (АГТ) у пациента с учетом его индивидуальных особенностей.

1. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13 (6): 4-11. @@ Muromtseva G.A., Kontsevaia A.V., Konstantinov V.V. i dr. Rasprostranennost' faktorov riska neinfektsionnykh zabolevanii v rossiiskoi populiatsii v 2012-2013 gg. Rezul'taty issledovaniia ESSE-RF. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 13 (6): 4-11.

2. Kearney P.M, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.

3. Piepoli M.F, Hoes A.W, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati).

4. Aktas M.K, Ozduran V, Pothier C.E et al. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA 2004; 292: 1462-8.

5. Hunt S.C, Williams R.R, Barlow G.K. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39: 809-21.

6. Friedman G.D, Selby J.V, Quesenberry C.P Jr et al. Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988; 17: 387-402.

7. Руководство по кардиологии в четырех томах. Под ред. акад. Е.И.Чазова. Т. 3: Заболевания сердечно-сосудистой системы (I). М.: Практика, 2014. @@ Rukovodstvo po kardiologii v chetyrekh tomakh. Pod red. akad. E.I.Chazova. T. 3: Zabolevaniia serdechno-sosudistoi sistemy (I). M.: Praktika, 2014.

8. Benetos A, Rudnichi A, Thomas F et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33: 44-52.

9. Julius S, Palatini P, Kjeldsen S.E et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109: 685-92.

10. Matsushita K, van der Velde M, Astor B.C et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.

11. De Leeuw P.W, Thijs L, Birkenhager W.H et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-22.

12. Rahman M, Pressel S, Davis B.R et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-80.

13. Stergiou G.S, Alpert B, Mieke S et al. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ ESH/ISO) Collaboration Statement. J Hypertens 2018; 36: 472-8.

14. Sehestedt T, Jeppesen J, Hansen T.W et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91.

15. Volpe M, Battistoni A, Tocci G et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012; 30: 1056-64.

16. Bacharova L, Schocken D, Estes E.H, Strauss D. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev 2014; 10: 257-61.

17. Pahor M, Guralnik J.M, Ambrosius W.T et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 2014; 311: 2387-96.

18. Lehtonen A.O, Puukka P, Varis J et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016; 34: 959-66.

19. Levy D, Salomon M, D’Agostino R.B et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-93.

20. Okin P.M, Devereux R.B, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-9.

21. Fagard R.H, Staessen J.A, Thijs L et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44: 459-64.

22. Kirchhof P, Lip G.Y, Van Gelder I.C, Bax J et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14 (1): 8-27. DOI: 10.1093/europace/eur241. Epub 2011 Jul 26. Review. PubMed PMID: 21791573; PubMed Central PMCID: PMC3236658.

23. Levy D, Garrison R.J, Savage D.D et al. Prognostic implications of Hypertension 2010; 56: 91-8.

24. Verdecchia P, Schillaci G, Borgioni C et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-8.

25. Muiesan M.L, Salvetti M, Monteduro C et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731-8.

26. Cuspidi C, Ambrosioni E, Mancia G et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20: 1307-14.

27. Boggia J, Li Y, Thijs L et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 1219-29.

28. Fagard R.H, Celis H, Thijs L et al. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.

29. Mancia G, Facchetti R, Bombelli M et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47: 846-53.

30. Fagard R.H, Cornelissen V.A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens 2007; 25: 2193-8.

31. Franklin S.S, Thijs L, Hansen T.W et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012; 59 (3): 564-71.

32. Bobrie G, Clerson P, Menard J et al. Masked hypertension: a systematic review. J Hypertens 2008; 26: 1715-25.

33. Longstreth W.T Jr, Manolio T.A, Arnold A et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27: 1274-82.

34. Vermeer S.E, Longstreth W.T Jr, Koudstaal P.J. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6 (7): 611-9. PubMed PMID: 17582361.

35. Boutouyrie P, Tropeano A.I., Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-5.

36. Pyörälä K, De Backer G, Graham I et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15 (10): 1300-31. PubMed PMID: 7821306.

37. D’Agostino R.B Sr, Vasan R.S, Pencina M. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753.

38. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-701.

39. Sundstrom J, Arima H, Jackson R et al., Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162: 184-91.

40. De Buyzere M.L, Clement D.L. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50: 238-63.

41. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.

42. Lonn E.M, Bosch J, Lopez-Jaramillo P et al., HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2009-20.

43. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923-34.

44. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018; 178: 28-36.

45. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.

46. Graudal N.A, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012; 25: 1-15.

47. Taylor R.S, Ashton K.E, Moxham T et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011; 24: 843-53.

48. Aburto N.J, Ziolkovska A, Hooper L et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ 2013; 346: f1326.

49. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.

50. Dickinson H.O, Mason J.M, Nicolson D.J et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24: 215-33.

51. Estruch R, Ros E, Salas-Salvado J et al, PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-90.

52. Mente A, de Koning L, Shannon H.S, Anand S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169: 659-69.

53. Sofi F, Abbate R, Gensini G.F, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an upd ated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189-96.

54. Neter J.E, Stam B.E, Kok F.J et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-84.

55. Flegal K.M, Kit B.K, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71-82.

56. Berrington de Gonzalez A, Hartge P, Cerhan J.R et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-9.

57. Leitzmann M.F, Park Y, Blair A et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007; 167: 2453-60.

58. Rossi A, Dikareva A, Bacon S.L, Daskalopoulou S.S. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens 2012; 30: 1277-88.

59. Lim S.S, Vos T, Flaxman A.D et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-60.

60. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.

61. Parving H.H, Brenner B.M, McMurray J.J et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.

62. Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603-15.

63. Ettehad D, Emdin C.A, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-67.

64. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33: 1321-41.

65. Rutten F.H, Zuithoff NP, Halk F et al. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7.

66. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management: is nice always good? J Hypertens 2012; 30: 660-8.

67. Wald D.S, Law M, Morris J.K et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300.

68. Parving H.H, Brenner B.M., McMurray J.J et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.

69. Dahlof B, Sever P.S, Poulter N.R et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.

70. Jamerson K, Weber M.A, Bakris G.L et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.

71. Matsuzaki M, Ogihara T, Umemoto S et al., Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011;29:1649-59.

72. MacDonald T.M, Williams B, Webb D.J et al., British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017; 6: e006986.

73. Yusuf S, Lonn E, Pais P et al., HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016; 374: 2032-43.

74. Xu W, Goldberg S.I, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015; 350: h158.

75. Egan B.M, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124-31.

76. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016; 34: 1921-32.

77. Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26: 819-24.

78. Corrao G, Parodi A, Zambon A et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584-90.

79. Gupta A.K, Arshad S, Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.

80. Weir M.R, Hsueh W.A, Nesbitt S.D et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil±hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13: 404-12.

81. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649-64.

82. ONTARGET Investigators, Yusuf S, Teo K.K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.

83. Sever P.S, Dahlof B, Poulter N.R et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.

84. Catapano A.L, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058.

85. Cholesterol Treatment Trialists’ Collaboration, Fulcher J, O’Connell R, Voysey M et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-405.

86. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017; 3 (28): 5-22. @@ Ezhov M.V., Sergienko I.V., Aronov D.M. i dr. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii VI peresmotr. Ateroskleroz i dislipidemii. 2017; 3 (28): 5-22.

87. Yusuf S, Bosch J, Dagenais G et al., HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021-31.

88. Lip G.Y, Felmeden D.C, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2011; 12: CD003186.

89. Inzucchi S.E, Bergenstal R.M, Buse J.B et al. Management of hyperglycaemia in type 2 diabetes: a patientcentreed approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.

90. Marso S.P, Daniels H, Brown-Frandsen K et al., LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-22.

91. Zinman B, Wanner C, Lachin J.M et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.

92. Neal B, Perkovic V, Mahaffey K.W et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-57.

93. Huang Y, Huang W, Mai W et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35: 677-88.

94. Bakris G.L, Serafidis P.A, Weir M.R et al., ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomised controlled trial. Lancet 2010; 375: 1173-81.

95. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.

96. DL Bhatt, Kandzari D.E, Controlled Trial of Renal Denervation for Resistant Hypertension. N Engl J Med 2014; 370: 1393-401.

97. Parving H.H, Brenner B.M, McMurray J.J.V et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.

98. Banegas J.R, Ruilope L.M, de la Sierra A et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018; 378: 1509-52.

99. Bobrie G, Clerson P, Menard J et al. Masked hypertension: a systematic review. J Hypertens 2008; 26: 1715-25.

100. Mancia G, Facchetti R, Bombelli M et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846-53.

101. Ogedegbe G, Agyemang C, Ravenell J.E. Masked hypertension: evidence of the need to treat. Curr Hypertens Rep 2010; 12: 349-55.

102. Banegas J.R, Ruilope L.M, de la Sierra A et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014; 35: 3304-12.

103. Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart 2014; 100: 317-23.

104. Odden M.C, McClure L.A, Sawaya B.P et al. Achieved blood pressure and outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 2016; 67: 63-9.

105. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - upd ated overview and meta-analyses of randomized trials. J Hypertens. 2016; 34 (4): 613-22. DOI: 10.1097/HJH.0000000000000881. PubMed PMID: 26848994.

106. Beckett N, Peters R, Leonetti G et al., HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens 2014; 32: 1478-87.

107. Vishram J.K, Borglykke A, Andreasen A.H et al., MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension 2012; 60: 1117-23.

108. Julius S, Nesbitt S.D, Egan B.M et al., Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-97.

109. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels-overview and meta-analyses of randomized trials. J Hypertens 2014; 32: 22.

110. He F.J, Li J, Macgregor G.A. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013; 4: CD004937.

111. Wijkman M, Lanne T, Engvall J et al. Masked nocturnal hypertension-a novel marker of risk in type 2 diabetes. Diabetologia 2009; 52: 1258-64.

112. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717.

113. Bakris G.L, Sarafidis P.A, Weir M.R et al., ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-81.

114. Cirillo M, Terradura-Vagnarelli O, Mancini M et al. Cohort profile: the Gubbio Population Study. Int J Epidemiol 2014; 43: 713-20.

115. Rodriguez-Luna D, Pineiro S, Rubiera M et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol 2013; 20: 1277-83.

116. Sakamoto Y, Koga M, Yamagami H et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke 2013; 44: 1846-51.

117. Anderson C.S, Heeley E, Huang Y et al., INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-65.

118. Qureshi A.I, Palesch Y.Y, Barsan W.G et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375: 1033-1.

119. Tsivgoulis G, Katsanos A.H, Butcher K.S et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 2014; 83: 1523-29.

120. Lee M, Ovbiagele B, Hong K.S et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke 2015; 46: 1883-9.

121. Zhao R, Liu F.D, Wang S et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or longterm dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore) 2015; 94: e896.

122. Ahmed N, Wahlgren N, Brainin M et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40: 2442-49.

123. Wu W, Huo X, Zhao X et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016; 11: e0144260.

124. Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157-72.

125. Jauch E.C, Saver J.L, Adams H.P Jr et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.

126. Sandset E.C., Bath P.M, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind tri.

127. Sandse t E.C, Murray G.D, Bath P.M et al.; Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Stroke 2012; 43: 2108-14.

128. Arima H, Chalmers J, Woodward M etal. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24: 120.

129. Bartsch E, Medcalf K.E, Park A.L, Ray J.G. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016; 353: i1753.

130. Snyder H.M, Corriveau R.A, Craft S et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement 2015; 11: 710-7.

131. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387: 435-43.

132. Yusuf S, Hawken S, Ounpuu S et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.

133. Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

134. Aboyans V, Ricco J.B, Bartelink M.E.L et al. The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2017; 39: 763-816.

135. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.

136. Tsai W.C, Wu H.Y, Peng Y.S et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017; 177: 792-9.

137. Lv J, Ehteshami P, Sarnak M.J et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013; 185: 949-57.

138. Malhotra R, Nguyen H.A, Benavente O et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med 2017; 177: 1498-505.

139. Jafar T.H, Stark P.C, Schmid C.H et al., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-52.

140. Sim J.J, Shi J, Kovesdy C.P et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014; 64: 588-97.

141. Redman C.W. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976; 2: 753-6.

142. Cockburn J, Moar V.A, Ounsted M, Redman C.W. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1: 647-9.

143. Koopmans C.M, Bijlenga D, Groen H et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-88.

144. Lubianca J.N, Moreira L.B, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005; 19: 451-5.

145. Mosca L, Benjamin E.J, Berra K et al. Effectiveness-based guidelinesforthe prevention ofcardiovasculardisease in women: 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011; 57: 1404-23.

146. Collins P, Rosano G, Casey C et al. Management of cardiovascular risk in the peri-menopausal woman: a сonsensus statement of European cardiologists and gynaecologists. Eur Heart J 2007; 28: 2028-40.

147. Jain M, Townsend R.R. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320-8.

148. Abi Aad S, Pierce M, Barmaimon G et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol 2015; 93: 28-35.

149. Chang H.M, Okwuosa T.M, Scarabelli T et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 2017; 70: 2552-65.

150. Milan A, Puglisi E, Ferrari L et al. Arterial hypertension and cancer. Int J Cancer 2014; 134: 2269-77.

151. Pimenta E, Gaddam K.K, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475-81.

152. Williams B, MacDonald T.M, Morant S et al., British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-68.

153. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens 2017; 39: 257-63.

154. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ 2016; 25: 1021-30.

155. Williams B, MacDonald T.M, Morant S.V et al., British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018; 6: 464-75.

156. Bhatt D.L, Kandzari D.E, O’Neill W.W et al., for the Symplicity HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-401.

157. Mathiassen O.N, Vase H, Bech J.N et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens 2016; 34: 1639-47.

158. Rimoldi S.F, Scherrer U, Messerli F.H. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245-54.

159. Viera A.J, Neutze D.M. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician 2010; 82 (12): 1471-8.

160. Calhoun D.A, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): 510-26.

161. Grossman A, Messerli F.H, Grossman E. Drug induced hypertension-An unappreciated cause of secondary hypertension. Eur J Pharmacol 2015; 763: 15-22.

162. Funder J.W, Carey R.M, Mantero F et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889-916.

163. Chester E.M, Agamanolis D.P, Banker B.Q, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology 1978; 28: 928-39.

164. Van den Born B.J, Koopmans R.P et al. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 2006; 24: 2299-304.

165. Cremer A, Amraoui F, Lip G.Y et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 2016; 30: 463-6.

166. Pinna G, Pascale C, Fornengo P et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One 2014; 9: e93542.

167. Van den Born B.J, Lowenberg E.C, van der Hoeven N.V et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 2011; 29: 922-7.

168. Van den Born B.J, Lip G.Y.H, Brguljan-Hitij J et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018; DOI:10.1093/ehjcvp/pvy032

169. Birtwhistle R.V, Godwin M.S, Delva M.D et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ 2004; 328: 204.

170. McManus R.J, Mant J, Bray E.P et al. Telemonitoring and selfmanagement in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010; 376: 163-72.

171. Bray E.P, Holder R, Mant J, McManus R.J. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med 2010; 42: 371-86.

172. Niiranen T.J, Hanninen M.R, Johansson J et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 2010; 55: 1346-51.

173. Fletcher B.R, Hartmann-Boyce J, Hinton L, McManus R.J. The effect of selfmonitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015; 28: 1209-21.